Lutein and zeaxanthin and their roles in age-related macular degeneration-neurodegenerative disease
10.1098/rstb.1999.0471 135
Key regulatory points for Epitalon Australia compliance: Epitalon is not approved by the Therapeutic Goods Administration (TGA) as a registered medicine for human or veterinary use It is classified strictly for laboratory and research purposes, not for human consumption Supply, import, and handling of research peptides fall under Australian regulatory oversight, and institutions should confirm current scheduling status directly through TGA resources before procurement Any research involving human subjects must comply with Research Ethics Committee approval and applicable Good Clinical Practice standards Marketing or supplying Epitalon with therapeutic claims, or implying suitability for human treatment, falls outside permitted research-use classifications Researchers and institutions should treat Epitalon strictly as a laboratory reagent, ensuring internal documentation, handling protocols, and communications consistently reflect its research-only status
Kaur N, Kumari A, Agarwal A, Sabharwal M, Dipti S (2022) Utilisation of Diospyros kaki L
HMGB1 mediates synaptic loss and cognitive impairment in an animal model of sepsis-associated encephalopathy
